Readmission After Surgical Resection and Transplantation for Hepatocellular Carcinoma: A Retrospective Cohort Study.
Carcinoma, Hepatocellular
/ mortality
Databases, Factual
Female
Hepatectomy
/ mortality
Humans
Liver Neoplasms
/ mortality
Liver Transplantation
/ mortality
Male
Middle Aged
Mortality
/ trends
Patient Readmission
/ statistics & numerical data
Retrospective Studies
Time Factors
United States
/ epidemiology
hepatocellular carcinoma
live resection
liver transplant
Journal
The American surgeon
ISSN: 1555-9823
Titre abrégé: Am Surg
Pays: United States
ID NLM: 0370522
Informations de publication
Date de publication:
Jan 2022
Jan 2022
Historique:
pubmed:
29
12
2020
medline:
24
12
2021
entrez:
28
12
2020
Statut:
ppublish
Résumé
Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality worldwide. Liver resections and transplantations have increasingly become feasible options for potential cure. These complex surgeries are inherently associated with increased rates of readmission. In the meanwhile, hospital readmission rates are rapidly becoming an important quality of care metric. Therefore, it is very important to understand the effect of 30-day readmission on mortality and the factors associated with increased 30- and 90-day mortality rates. This is a retrospective cohort study utilizing data from the National Cancer Database. Patients included were 18 years or older who underwent liver resection or liver transplantation for HCC between 2003 and 2011. Our primary outcomes of interest were 30- and 90-day mortality rates. Our primary independent variable of interest was 30-day readmission. 16 658 patients underwent either a liver resection or transplantation for HCC between 2003 and 2011. For patients with liver transplantations, increased readmission rates were associated with lower risks of 30-day mortality ( This is the only study to utilize a national database to investigate the association between readmission rates and mortality rates of both liver transplantations and resections for patients with HCC. We demonstrate 30-day readmission to show no increase in 30-day mortality, but rather higher 90-day mortality.
Sections du résumé
BACKGROUND
BACKGROUND
Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality worldwide. Liver resections and transplantations have increasingly become feasible options for potential cure. These complex surgeries are inherently associated with increased rates of readmission. In the meanwhile, hospital readmission rates are rapidly becoming an important quality of care metric. Therefore, it is very important to understand the effect of 30-day readmission on mortality and the factors associated with increased 30- and 90-day mortality rates.
METHODS
METHODS
This is a retrospective cohort study utilizing data from the National Cancer Database. Patients included were 18 years or older who underwent liver resection or liver transplantation for HCC between 2003 and 2011. Our primary outcomes of interest were 30- and 90-day mortality rates. Our primary independent variable of interest was 30-day readmission.
RESULTS
RESULTS
16 658 patients underwent either a liver resection or transplantation for HCC between 2003 and 2011. For patients with liver transplantations, increased readmission rates were associated with lower risks of 30-day mortality (
CONCLUSION
CONCLUSIONS
This is the only study to utilize a national database to investigate the association between readmission rates and mortality rates of both liver transplantations and resections for patients with HCC. We demonstrate 30-day readmission to show no increase in 30-day mortality, but rather higher 90-day mortality.
Identifiants
pubmed: 33369487
doi: 10.1177/0003134820973739
pmc: PMC8236493
mid: NIHMS1667745
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
83-92Subventions
Organisme : NCI NIH HHS
ID : T32 CA113263
Pays : United States
Commentaires et corrections
Type : CommentIn
Références
J Am Coll Surg. 2012 Nov;215(5):607-15
pubmed: 22921328
Liver Transpl. 2012 Sep;18(9):1037-45
pubmed: 22639419
Ann Surg. 2003 Aug;238(2):161-7
pubmed: 12894006
Br J Surg. 2011 Sep;98(9):1292-300
pubmed: 21656513
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
J Clin Epidemiol. 1992 Jun;45(6):613-9
pubmed: 1607900
Ann Surg. 2014 Aug;260(2):244-51
pubmed: 24368634
HPB (Oxford). 2011 Oct;13(10):712-22
pubmed: 21929672
J Am Coll Surg. 2013 May;216(5):915-23
pubmed: 23518253
Acta Orthop. 2011 Feb;82(1):20-6
pubmed: 21067430
J Clin Oncol. 2014 Dec 20;32(36):4113-9
pubmed: 25385738
Cancer. 2012 Apr 1;118(7):1838-44
pubmed: 22009384
World J Gastroenterol. 2013 Nov 14;19(42):7316-26
pubmed: 24259963
N Engl J Med. 2002 Apr 11;346(15):1128-37
pubmed: 11948273
Ann Surg. 2011 Apr;253(4):745-58
pubmed: 21475015